AG
SYRE icon

Algert Global’s Spyre Therapeutics SYRE Stock Holding History

Algert Global’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,278
Closed -$131K – 1379
2022
Q1 		$131K Buy
2,278
+981
+76% +$82.4K 0.01% 1085
2021
Q4 		$154K Sell
1,297
-175
-12% -$27.6K 0.02% 888
2021
Q3 		$293K Sell
1,472
-188
-11% -$32.9K 0.04% 768
2021
Q2 		$289K Sell
1,660
-1,013
-38% -$184K 0.1% 293
2021
Q1 		$529K Sell
2,673
-1,475
-36% -$283K 0.17% 197
2020
Q4 		$816K Sell
4,148
-174
-4% -$36.1K 0.23% 156
2020
Q3 		$766K Buy
+4,322
New +$800K 0.24% 149
2019
Q4 		– Sell
-936
Closed -$180K – 435
2019
Q3 		$180K Buy
936
+54
+6% +$10.5K 0.07% 290
2019
Q2 		$151K Buy
882
+148
+20% +$25.6K 0.06% 300
2019
Q1 		$148K Sell
734
-293
-29% -$61.1K 0.08% 263
2018
Q4 		$192K Buy
+1,027
New +$218K 0.05% 336

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Algert Global's SYRE Position: Q2 2022 in Review

Algert Global sold out of Spyre Therapeutics (SYRE) in Q2 2022, closing a stake of 2,278 shares — an estimated $131K sold.

Algert Global first reported a position in SYRE in Q4 2018 and held it in 11 quarters. The position peaked at $816K in Q4 2020. 66 funds tracked by Wall St. Rank hold SYRE as of Q2 2022.

  • Algert Global reported no remaining Spyre Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Algert Global sold 2,278 Spyre Therapeutics shares in Q2 2022, an estimated $131K.
  • Algert Global first reported a position in Spyre Therapeutics in Q4 2018 and held it in 11 quarters.
  • Algert Global's Spyre Therapeutics position peaked at $816K in Q4 2020.
  • 66 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2022.

Based on Algert Global's 13F filing for Q2 2022, filed 15 Aug 2022.